Alkem Laboratories delivered Q1 FY27 revenue growth of 10.9% YoY to ₹3,740 crore, while EBITDA rose 3.7% to ₹766 crore. PAT declined 21.7% to ₹520 crore, largely reflecting the high base and tax impact. Domestic sales grew 10.3% to ₹2,498 crore, outperforming the Indian pharma market, while US sales increased 6.5% to ₹744 crore.  Latest News: Alkem launched semaglutide in India in March 2026 and became the first Indian company to launch it in single-shot pre-filled syringes in June, with pricing starting at ₹350. The company also received 5 ANDA approvals in Q1. Corporate Action/Catalysts: Alkem had ₹5,764 crore net cash at June 2026 and continues investing in R&D, with Q1 R&D spend at ₹150 crore. Strong domestic brands, semaglutide potential and US launches provide growth catalysts. Key risks include US pricing pressure, regulatory issues and margin moderation. 

#HiddenGems

648 likes·59 comments